Iovance and Amgen Are Making Cancer History
Advances by the two companies offer hope for patients and may attract more investment in unique approaches to difficult forms of the disease.
An annual oncology confab yields promising research results.
Photographer: Tim Boyle/Bloomberg
The annual meeting of the American Society of Clinical Oncology (ASCO), which wrapped up Tuesday, is one of the drug industry’s most prominent platforms for showcasing promising cancer research and treatments. This year was no exception.
While there wasn’t as much late-stage blockbuster data to pore over as in years past, there was plenty of exciting progress to celebrate among efforts to tackle tough cancers. Early results from Iovance Biotherapeutics Inc. in cervical cancer and Amgen Inc. in lung cancer were particular standouts, and broke new scientific ground.